Search

Your search keyword '"Jin, Eun-Sun"' showing total 204 results
Start Over Author "Jin, Eun-Sun"
204 results on '"Jin, Eun-Sun"'

1. Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: Rationale and design of the randomized EPIC-CAD trial

Author

Cho, Min Soo, Kang, Do-Yoon, Oh, Yong-Seog, Lee, Chang Hoon, Choi, Eue-Keun, Lee, Ji Hyun, Kwon, Chang Hee, Park, Gyung-Min, Park, Hyun Woo, Park, Kyoung-Ha, Park, Kyoung-Min, Hwang, Jongmin, Yoo, Ki-Dong, Cho, Young-Rak, Kim, Yoo Ri, Hwang, Ki Won, Jin, Eun Sun, Kim, Pum-Joon, Kim, Ki Hun, Park, Duk-Woo, and Nam, Gi-Byoung

Published
2022
Full Text
View/download PDF

6. Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk:A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS-SPAF)

Author

Jung, Moonki, Byeon, Kyeongmin, Kang, Ki-Woon, Lee, Wang-Soo, Kim, Sang Wook, Park, Yae Min, Hwang, You Mi, Lee, Sung Ho, Jin, Eun-Sun, Roh, Seung-Young, Kim, Jin Seok, Ahn, Jinhee, Lee, So-Ryoung, Choi, Eue-Keun, Ahn, Min-Soo, Lee, Eun Mi, Park, Hwan-Cheol, Lee, Ki Hong, Kim, Min, Choi, Joon Hyouk, Ko, Jum Suk, Kim, Jin Bae, Kim, Changsoo, Lip, Gregory Y. H., and Shin, Seung Yong

Subjects
net clinical benefit, ABCD score, non-vitamin K antagonist oral anticoagulant, atrial fibrillation, antithrombotic treatment
Abstract

BackgroundThe balance of stroke risk reduction and potential bleeding risk associated with antithrombotic treatment (ATT) remains unclear in atrial fibrillation (AF) at non-gender CHA2DS2-VASc scores 0–1. A net clinical benefit (NCB) analysis of ATT may guide stroke prevention strategies in AF with non-gender CHA2DS2-VASc scores 0–1.MethodsThis multi-center cohort study evaluated the clinical outcomes of treatment with a single antiplatelet (SAPT), vitamin K antagonist (VKA), and non-VKA oral anticoagulant (NOAC) in non-gender CHA2DS2-VASc score 0–1 and further stratified by biomarker-based ABCD score (Age [≥60 years], B-type natriuretic peptide [BNP] or N-terminal pro-BNP [≥300 pg/mL], creatinine clearance [ResultsWe included 2465 patients (age 56.2 ± 9.5 years; female 27.0%) followed-up for 4.0 ± 2.8 years, of whom 661 (26.8%) were treated with SAPT; 423 (17.2%) with VKA; and 1040 (42.2%) with NOAC. With detailed risk stratification using the ABCD score, NOAC showed a significant positive NCB compared with the other ATTs (SAPT vs. NOAC, NCB 2.01, 95% confidence interval [CI] 0.37–4.66; VKA vs. NOAC, NCB 2.38, 95% CI 0.56–5.40) in ABCD score ≥1. ATT failed to show a positive NCB in patients with truly low stroke risk (ABCD score = 0).ConclusionsIn the Korean AF cohort at non-gender CHA2DS2-VASc scores 0–1, NOAC showed significant NCB advantages over VKA or SAPT with ABCD score ≥1. BackgroundThe balance of stroke risk reduction and potential bleeding risk associated with antithrombotic treatment (ATT) remains unclear in atrial fibrillation (AF) at non-gender CHA2DS2-VASc scores 0–1. A net clinical benefit (NCB) analysis of ATT may guide stroke prevention strategies in AF with non-gender CHA2DS2-VASc scores 0–1.MethodsThis multi-center cohort study evaluated the clinical outcomes of treatment with a single antiplatelet (SAPT), vitamin K antagonist (VKA), and non-VKA oral anticoagulant (NOAC) in non-gender CHA2DS2-VASc score 0–1 and further stratified by biomarker-based ABCD score (Age [≥60 years], B-type natriuretic peptide [BNP] or N-terminal pro-BNP [≥300 pg/mL], creatinine clearance [ResultsWe included 2465 patients (age 56.2 ± 9.5 years; female 27.0%) followed-up for 4.0 ± 2.8 years, of whom 661 (26.8%) were treated with SAPT; 423 (17.2%) with VKA; and 1040 (42.2%) with NOAC. With detailed risk stratification using the ABCD score, NOAC showed a significant positive NCB compared with the other ATTs (SAPT vs. NOAC, NCB 2.01, 95% confidence interval [CI] 0.37–4.66; VKA vs. NOAC, NCB 2.38, 95% CI 0.56–5.40) in ABCD score ≥1. ATT failed to show a positive NCB in patients with truly low stroke risk (ABCD score = 0).ConclusionsIn the Korean AF cohort at non-gender CHA2DS2-VASc scores 0–1, NOAC showed significant NCB advantages over VKA or SAPT with ABCD score ≥1.

Published
2023

10. Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA2DS2-VASc Score 0-1:A Korean Multi-Center Cohort

Author

Jung, Moonki, Byeon, Kyeongmin, Kang, Ki-Woon, Park, Yae Min, Hwang, You Mi, Lee, Sung Ho, Jin, Eun-Sun, Roh, Seung-Young, Kim, Jin Seok, Ahn, Jinhee, Lee, So-Ryoung, Choi, Eue-Keun, Ahn, Min-Soo, Lee, Eun Mi, Park, Hwan-Cheol, Lee, Ki Hong, Kim, Min, Choi, Joon Hyouk, Ko, Jum Suk, Kim, Jin Bae, Kim, Changsoo, Lip, Gregory Y. H., and Shin, Seung Yong

Subjects
Stroke/etiology, ABCD score, General Medicine, risk stratification, Middle Aged, Risk Assessment, Atrial fibrillation, stroke, Cohort Studies, Anticoagulants/therapeutic use, Fibrinolytic Agents, Risk Factors, Creatinine, Natriuretic Peptide, Brain, Humans, Female, Republic of Korea/epidemiology, Atrial Fibrillation/complications, Biomarkers, Retrospective Studies
Abstract

Purpose: Atrial fibrillation (AF) patients with low to intermediate risk, defined as non-gender CHA 2DS 2-VASc score of 0–1, are still at risk of stroke. This study verified the usefulness of ABCD score [age (≥60 years), B-type natriuretic peptide (BNP) or N-ter-minal pro-BNP (≥300 pg/mL), creatinine clearance (2), and dimension of the left atrium (≥45 mm)] for stroke risk stratification in non-gender CHA 2DS 2-VASc score 0–1. Materials and Methods: This multi-center cohort study retrospectively analyzed AF patients with non-gender CHA 2DS 2-VASc score 0–1. The primary endpoint was the incidence of stroke with or without antithrombotic therapy (ATT). An ABCD score was validated. Results: Overall, 2694 patients [56.3±9.5 years; female, 726 (26.9%)] were followed-up for 4.0±2.8 years. The overall stroke rate was 0.84/100 person-years (P-Y), stratified as follows: 0.46/100 P-Y for an ABCD score of 0; 1.02/100 P-Y for an ABCD score ≥1. The ABCD score was superior to non-gender CHA 2DS 2-VASc score in the stroke risk stratification (C-index=0.618, p=0.015; net reclassi-fication improvement=0.576, p=0.040; integrated differential improvement=0.033, p=0.066). ATT was prescribed in 2353 patients (86.5%), and the stroke rate was significantly lower in patients receiving non-vitamin K antagonist oral anticoagulant (NOAC) therapy and an ABCD score ≥1 than in those without ATT (0.44/100 P–Y vs. 1.55/100 P-Y; hazard ratio=0.26, 95% confidence interval 0.11–0.63, p=0.003). Conclusion: The biomarker-based ABCD score demonstrated improved stroke risk stratification in AF patients with non-gender CHA 2DS 2-VASc score 0–1. Furthermore, NOAC with an ABCD score ≥1 was associated with significantly lower stroke rate in AF patients with non-gender CHA 2DS 2-VASc score 0–1.

Published
2022

12. Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF).

Author

Jung, Moonki, Byeon, Kyeongmin, Kang, Ki‐Woon, Lee, Wang‐Soo, Kim, Sang Wook, Park, Yae Min, Hwang, You Mi, Lee, Sung Ho, Jin, Eun‐Sun, Roh, Seung‐Young, Kim, Jin Seok, Ahn, Jinhee, Lee, So‐Ryoung, Choi, Eue‐Keun, Ahn, Min‐Soo, Lee, Eun Mi, Park, Hwan‐Cheol, Lee, Ki Hong, Kim, Min, and Choi, Joon Hyouk

Subjects
STROKE prevention, HEMORRHAGE risk factors, ANTICOAGULANTS, RISK assessment, RESEARCH funding, ORAL drug administration, FIBRINOLYTIC agents, VITAMIN K, TREATMENT effectiveness, PEPTIDE hormones, DESCRIPTIVE statistics, SURVEYS, LONGITUDINAL method, ATRIAL fibrillation, RESEARCH, STROKE, PLATELET aggregation inhibitors, CONFIDENCE intervals, DATA analysis software, BIOMARKERS, DISEASE risk factors, CHEMICAL inhibitors
Abstract

Background: The balance of stroke risk reduction and potential bleeding risk associated with antithrombotic treatment (ATT) remains unclear in atrial fibrillation (AF) at non‐gender CHA2DS2‐VASc scores 0–1. A net clinical benefit (NCB) analysis of ATT may guide stroke prevention strategies in AF with non‐gender CHA2DS2‐VASc scores 0–1. Methods: This multi‐center cohort study evaluated the clinical outcomes of treatment with a single antiplatelet (SAPT), vitamin K antagonist (VKA), and non‐VKA oral anticoagulant (NOAC) in non‐gender CHA2DS2‐VASc score 0–1 and further stratified by biomarker‐based ABCD score (Age [≥60 years], B‐type natriuretic peptide [BNP] or N‐terminal pro‐BNP [≥300 pg/mL], creatinine clearance [<50 mL/min], and dimension of the left atrium [≥45 mm]). The primary outcome was the NCB of ATT, including composite thrombotic events (ischemic stroke, systemic embolism, and myocardial infarction) and major bleeding events. Results: We included 2465 patients (age 56.2 ± 9.5 years; female 27.0%) followed‐up for 4.0 ± 2.8 years, of whom 661 (26.8%) were treated with SAPT; 423 (17.2%) with VKA; and 1040 (42.2%) with NOAC. With detailed risk stratification using the ABCD score, NOAC showed a significant positive NCB compared with the other ATTs (SAPT vs. NOAC, NCB 2.01, 95% confidence interval [CI] 0.37–4.66; VKA vs. NOAC, NCB 2.38, 95% CI 0.56–5.40) in ABCD score ≥1. ATT failed to show a positive NCB in patients with truly low stroke risk (ABCD score = 0). Conclusions: In the Korean AF cohort at non‐gender CHA2DS2‐VASc scores 0–1, NOAC showed significant NCB advantages over VKA or SAPT with ABCD score ≥1. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Additional file 1 of Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases

Author

Seo, Won-Woo, Seo, Seung In, Kim, Yerim, Yoo, Jong Jin, Shin, Woon Geon, Kim, Jinseob, You, Seng Chan, Park, Rae Woong, Park, Young Min, Kim, Kyung-Jin, Rhee, Sang Youl, Park, Meeyoung, Jin, Eun-Sun, and Kim, Sung Eun

Subjects
health services administration, nutritional and metabolic diseases, heterocyclic compounds, lipids (amino acids, peptides, and proteins), cardiovascular diseases
Abstract

Additional file 1: Table S1. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in KHNMC cohort. Table S2. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in WKUH cohort. Table S3. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in DCMC cohort. Table S4. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in AUMC cohort. Table S5. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in PNUH cohort. Table S6. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in EUMC cohort. Table S7. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in NHIMC cohort. Table S8. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in MJH cohort. Table S9. Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in KWMC cohort.

Published
2022
Full Text
View/download PDF

26. Bone formation effect of highly concentrated tricalcium phosphate biocomposite screws in a rabbit osteoporosis model.

Author

Jeong, Je Hoon, Jin, Eun‐Sun, Kim, Ji Yeon, Min, JoongKee, Jeon, Sang Ryong, Lee, Minsu, and Choi, Kyoung Hyo

Subjects
*BONE growth, *BONE density, *STAINS & staining (Microscopy), *LUMBAR vertebrae, *SCREWS, *CANCELLOUS bone
Abstract

The purpose of this study was to determine the efficacy of highly concentrated tricalcium phosphate (TCP) biocomposite screws on local bone formation in a rabbit model of osteoporosis induced by bilateral ovariohysterectomy (OHE). Fourteen 24‐week‐old female New Zealand rabbits (weight, 3–3.5 kg) were divided into two groups: (1) OHE and biodegradable poly(lactic‐co‐glycolic acid) (PLGA) without ß–TCP plate or screw insertion (OHE/Bio ScRew [BSR]) group and (2) OHE and biocomposite PLGA with highly concentrated ß–TCP plate and screw insertion (OHE/highly concentrated ß–triCalcium phosphate [HCCP]). Both groups underwent bilateral OHE and had two different types of screws and plates inserted at the proximal tibia. Bilateral tibiae were extracted at 25 weeks post‐OHE. The extracted tibiae were scanned with ex vivo microcomputed tomography (micro‐CT). Parameters including bone mineral density (BMD), trabecular bone volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb. Th), and trabecular separation (Tb. Sp) were evaluated after staining the tibial samples with hematoxylin and eosin (H&E) and Masson's trichrome. We then performed pathological assessments. Micro‐CT images revealed improved new bone formation near the implant in the OHE/HCCP group with higher values of BMD, BV/TV, and Tb.N but lower values of Tb. Th and Tb. Sp than the OHE/BSR group. Analyses of H&E and Masson's trichrome staining showed better new bone formation around the implant in the OHE/HCCP group than in the OHE/BSR group. The use of highly concentrated TCP biocomposite screw and plate might improve local bone formation and facilitate osteoconductivity in an osteoporotic rabbit model. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Long-term Clinical Outcomes of Radiofrequency Catheter Ablation versus Permanent Pacemaker Implantation in Patients with Tachycardia-Bradycardia Syndrome

Author

Cho, Sang-Cheol, primary, Jin, Eun-Sun, additional, Om, Sang Yong, additional, Hwang, Ki Won, additional, Choi, Hyung Oh, additional, Kim, Ki-Hun, additional, Kim, Sung-Hwan, additional, Park, Kyoung-Min, additional, Kim, Jun, additional, Choi, Ki-Joon, additional, Kim, You-Ho, additional, and Nam, Gi-Byoung, additional

Published
2020
Full Text
View/download PDF

33. Status of international normalized ratio control and treatment patterns in patients with nonvalvular atrial fibrillation taking vitamin K antagonist with or without antiplatelet therapy: Results from KORAFII registry

Author

Park, Hee-Soon, primary, Kim, Young-Hoon, additional, Kim, June Soo, additional, Oh, Yong-Seog, additional, Shin, Dong-Gu, additional, Pak, Hui-Nam, additional, Hwang, Gyo-Seung, additional, Choi, Kee-Joon, additional, Oh, Seil, additional, Kim, Jin-Bae, additional, Lee, Man-Young, additional, Park, Hyung-Wook, additional, Kim, Dae-Kyeong, additional, Jin, Eun-Sun, additional, Park, Jae-Seok, additional, Oh, Il-Young, additional, Shin, Dae-Hee, additional, Park, Hyoung-Seob, additional, Kim, Jun Hyung, additional, Kim, Nam-Ho, additional, Ahn, Min-Soo, additional, Seo, Bo-Jeong, additional, Kim, Young-Joo, additional, Kang, Seongsik, additional, and Lee, Juneyoung, additional

Published
2019
Full Text
View/download PDF

38. 2018 KHRS Guidelines for Catheter Ablation of Ventricular Arrhythmias – Part2

Author

Kim, Ju-Youn, primary, Kim, Sung-Hwan, additional, Kim, Yoo Ri, additional, Kim, Yoon-Nyun, additional, Kim, Jun, additional, Kim, Tae-Hoon, additional, Nam, Gi-Byoung, additional, Roh, Seung-Young, additional, Park, Kyoung-Min, additional, Park, Hyoung-Seob, additional, Pak, Hui-Nam, additional, Bae, Eun-Jung, additional, Oh, Seil, additional, Yoon, Namsik, additional, Lee, Man Young, additional, Cho, Youngjin, additional, Cho, Yongkeun, additional, Jin, Eun-Sun, additional, Cha, Tae-Joon, additional, and Choi, Jong-Il, additional

Published
2018
Full Text
View/download PDF

39. 2018 KHRS Guidelines for Catheter Ablation of Ventricular Arrhythmias – Part3

Author

Cho, Youngjin, primary, Kim, Sung-Hwan, additional, Kim, Yoo Ri, additional, Kim, Yoon-Nyun, additional, Kim, Ju-Youn, additional, Kim, Tae-Hoon, additional, Nam, Gi-Byoung, additional, Roh, Seung-Young, additional, Park, Kyoung-Min, additional, Park, Hyoung-Seob, additional, Pak, Hui-Nam, additional, Bae, Eun-Jung, additional, Oh, Seil, additional, Yoon, Namsik, additional, Lee, Man Young, additional, Cho, Yongkeun, additional, Jin, Eun-Sun, additional, Cha, Tae-Joon, additional, Choi, Jong-Il, additional, and Kim, Jun, additional

Published
2018
Full Text
View/download PDF

40. 2018 KHRS Guidelines for Catheter Ablation of Ventricular Arrhythmias – Part1

Author

Roh, Seung-Young, primary, Kim, Sung-Hwan, additional, Kim, Yoon-Nyun, additional, Kim, Ju-Youn, additional, Kim, Jun, additional, Kim, Tae-Hoon, additional, Nam, Gi-Byoung, additional, Park, Kyoung-Min, additional, Park, Hyoung-Seob, additional, Pak, Hui-Nam, additional, Bae, Eun-Jung, additional, Oh, Seil, additional, Yoon, Namsik, additional, Lee, Man Young, additional, Cho, Youngjin, additional, Cho, Yongkeun, additional, Jin, Eun-Sun, additional, Cha, Tae-Joon, additional, Choi, Jong-Il, additional, and Kim, Yoo Ri, additional

Published
2018
Full Text
View/download PDF

42. Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II

Author

Oh, Seil, primary, Kim, June-Soo, additional, Oh, Yong-Seog, additional, Shin, Dong-Gu, additional, Pak, Hui-Nam, additional, Hwang, Gyo-Seung, additional, Choi, Kee-Joon, additional, Kim, Jin-Bae, additional, Lee, Man-Young, additional, Park, Hyung-Wook, additional, Kim, Dae-Kyeong, additional, Jin, Eun-Sun, additional, Park, Jaeseok, additional, Oh, Il-Young, additional, Shin, Dae-Hee, additional, Park, Hyoung-Seob, additional, Kim, Jun Hyung, additional, Kim, Nam-Ho, additional, Ahn, Min-Soo, additional, Seo, Bo-Jeong, additional, Kim, Young-Joo, additional, Kang, Seongsik, additional, Lee, Juneyoung, additional, and Kim, Young-Hoon, additional

Published
2018
Full Text
View/download PDF

46. Prognosis of Variant Angina Manifesting as Aborted Sudden Cardiac Death

Author

Ahn, Jung-Min, primary, Lee, Ki Hong, additional, Yoo, Sang-Yong, additional, Cho, Young-Rak, additional, Suh, Jon, additional, Shin, Eun-Seok, additional, Lee, Jae-Hwan, additional, Shin, Dong Il, additional, Kim, Sung-Hwan, additional, Baek, Sang Hong, additional, Seung, Ki Bae, additional, Nam, Chang-Wook, additional, Jin, Eun-Sun, additional, Lee, Se-Whan, additional, Oh, Jun-Hyok, additional, Jang, Jae Hyun, additional, Park, Hyung Wook, additional, Yoon, Nam Sik, additional, Cho, Jeong Gwan, additional, Lee, Cheol Hyun, additional, Park, Duk-Woo, additional, Kang, Soo-Jin, additional, Lee, Seung-Whan, additional, Kim, Jun, additional, Kim, Young-Hak, additional, Nam, Ki-Byung, additional, Lee, Cheol Whan, additional, Choi, Kee-Joon, additional, Song, Jae-Kwan, additional, Kim, You-Ho, additional, Park, Seong-Wook, additional, and Park, Seung-Jung, additional

Published
2016
Full Text
View/download PDF

47. ECG features and proarrhythmic potentials of therapeutic hypothermia

Author

Lee, Woo Seok, primary, Nam, Gi-Byoung, additional, Kim, Sung-Hwan, additional, Choi, Jin Hee, additional, Jo, Uk, additional, Kim, Won Young, additional, Oh, Yong-Seog, additional, Park, Kyu Nam, additional, Seo, Guang-Won, additional, Kim, Ki-Hun, additional, Jin, Eun-Sun, additional, Rhee, Kyoung-Suk, additional, Jung, Laeyoung, additional, Hwang, Ki-Won, additional, Kim, Yoo Ri, additional, Kwon, Chang Hee, additional, Kim, Jun, additional, Choi, Kee-Joon, additional, and Kim, You-Ho, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results